CVS) is a prominent player in the U.S. healthcare market, offering a broad spectrum of health solutions. The company has ...

CVS also reported its quarterly results today, with revenue exceeding but earnings missing the street estimates.

CVS Health has an analyst consensus of Moderate Buy, with a price target consensus of $68.15, implying a 26.13% upside from current levels. In a report released on November 11, TD Cowen also ...

CVS Health also revised its profit forecast downward for the ... which pressures profitability. The stock is down 22% year-to ...

Taking into account the latest results, the current consensus from CVS Health's 23 analysts is for revenues of US$385.9b in ...

CVS Health stock surged over 11% following a sizable revenue beat and the appointment of new CEO David Joyner. See why I'm ...

CVS’s stock surges after revenue rose well above expectations, while profit missed because of a large charge premium ...

CVS Health will report third-quarter earnings before the market opens Wednesday as the pharmacy and health-care provider ...

CVS Health rated Hold, offers dividend yield, facing challenges from CMS decisions and rising medical costs in healthcare ...

Shares of CVS Health Corp. CVS shed 7.37% to $57.07 Thursday, on what proved to be an all-around mixed trading session for ...

Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on CVS Health (CVS – Research Report). The associated price target was ...